Results vary, and no specific outcome is guaranteed
BPC-157, or Body Protecting Compound-157, is a 15-amino-acid peptide sequence (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) isolated from gastric juices.[1][2] It was first identified in the 1990s as part of research into cytoprotective agents that safeguard the gastrointestinal (GI) tract from damage.[3] Unlike many peptides, BPC-157 is highly stable in acidic environments, allowing for oral administration without significant degradation.[4] In compounding pharmacies, BPC-157 is often prepared as capsules, injectables, or topical formulations
Structurally dissimilar antimanic agents modulate synaptic plasticity by regulating AMPA glutamate receptor subunit GluR1 synaptic expression
Frequently asked questions Is penta deca peptide arginate the same as BPC-157
Expression of hepatocyte growth factor in the serum and cerebrospinal fluid of patients with Parkinsons disease
The regulatory landscape is evolving rapidly